Compare TRIB & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | ICU |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 15.9M |
| IPO Year | N/A | N/A |
| Metric | TRIB | ICU |
|---|---|---|
| Price | $0.74 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.4M | 113.4K |
| Earning Date | 02-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,409,000.00 | $881,000.00 |
| Revenue This Year | $13.51 | $691.85 |
| Revenue Next Year | $13.14 | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.48 | $2.20 |
| 52 Week High | $3.44 | $30.70 |
| Indicator | TRIB | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 89.58 |
| Support Level | $0.73 | $2.40 |
| Resistance Level | $1.75 | $2.81 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.03 | 0.28 |
| Stochastic Oscillator | 2.57 | 86.54 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.